BIBLIOGRAFIA
Aapro MS, Martin C e Hatty S. Gemcitabine. Anticancer Drugs 1998; 9: 191-201.
Adam GI. The development of pharmacogenomic models to predict drug response.
Curr Opin Drug Discov Devel 2001; 4: 296-300
Adjei AA, Davis JN, Bruzek LM, et al. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001; 7:
1438-1445.
Adjei AA, Erlichman C, Sloan AJ, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitarget antifolate agent in patients with advanced solid tumors.
J Clin Oncol 2000; 8: 1748-1757.
Adjei AA, Erlichman C, Thornton D, et al. Synergistic cytotoxicity of MTA (LY231514) and gemcitabine in vitro and in vivo. 10th NCI- EORTC Symposium on New Drugs in Cancer Therapy Ann Oncol 1998; 9: 168-172
Adjei AA. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Lung Cancer 2001; 34: 103-105.
Agami R. RNAi and related mechenisms and their potential use for therapy. Curr Chem Biol 2002; 6:829-834
Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-6551.
Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
Assaraf Y e Goldmann ID. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 1997; 272: 174-178.
Baiocchi C, Pesi R, Camici M, et al. Mechanism of the reaction catalysed by cytosolic 5'-nucleotidase/phosphotransferase: formation of a phosphorylated intermediate.
Biochem J 1996; 317: 797-801.
Baker CH, Banzon J, Bollinger JM, et al. 2'-Deoxy-2'-methylenecytidine and 2'- deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991; 34: 1879-1884.
Bandala E, Espinosa M, Maldonado V et al. Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine.
Biochem Pharmacol 2001; 62: 13-19.
Barale R. Farmaci e genoma. Incontri Glaxosmithkline, Società Italiana di Genetica Umana 2001; 2: 5-16.
Barale R. Farmaci e genoma. Incontri Glaxosmithkline, Società Italiana di Genetica Umana 2001; 2:5-16.
Barbour KW, Berger SH e Berger FG. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol 1990;
37: 515-518.
Barnes CJ, Lee M, Hardman WE et al. Aspirin, age, and proximity to lymphoid nodules influence cell proliferation parameters in rat colonic crypts. Cell Prolif 1995; 28:
59-71.
Barthwal MK, Sathyanarayana P, Kundu CN, et al. Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem 2003; 278:
3897-3902.
Bauer P, Rolfs A, Regitz-Zagrosek V, Hildebrandt A e Fleck E. Use of manganese in RT-PCR eliminates PCR artefacts resulting from DNAase digestion. Biotechniques 1997;
22: 1128-1132.
Beausejour CM, Eliopoulos N, Momparler L, et al. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther 2001; 8: 669-676.
Becker-Andre M. Absolute levels of mRNA by polymerase chain reaction-aided transcript titration assay. Methods in Enzymology 1993; 218: 420-445.
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Bailey Iacona R, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. J Clin Oncol. 2005.
Berger W, Elblinng L e Micksche M. Expression of the major valut protein LRP in human non-small cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000; 88: 293-300.
Bergman AM, Munch-Petersen B, Jensen PB, et al. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 2001; 61: 1401-1408.
Bergman AM, Pinedo HM e Peters GJ. Determinants of resistance to 2',2'- difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33.
Bergman AM, Pinedo HM, Jongsma AP, et al. Decreased resistance to (2',2'- Difluorodeoxycitidine) of cytosinearabinoside resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Biochem Pharmacol 1999; 57: 397-406.
Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003; 88: 1963-70.
Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-530.
Biondi RM, Kieloch A, Currie RA, et al. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 2001; 20: 4380-4390.
Boarman DM, Baram J e Allegra CJ. Interaction of polyglutamyl derivatives of methotrexate, 10-deazaaminopterin, and dihydrofolate with dihydrofolate reductase.
Cancer Res 1986; 46: 5020-5023.
Boddy A e Idle J. The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity. Cancer Sur 1993; 17: 79-109.
Boddy A e Idle J. The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity. Cancer Sur 1993; 17:79-109.
Borenfreund E, Babich H e Martin-Alguacil N. Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell Dev Biol 1990; 26: 1030-1034.
Bouffard D, Laliberté J e Momparler RL. Kinetic studies on 2',2'- difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine. Biochem Pharmacol 1993; 45: 1857-1861.
Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
Branch P, Masson M, Aquilina G, et al. Spontaneuous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000; 19: 3138-3145.
Britten CD, Izbicka E, Hilsenbeck S,et al. Activity of multitarget antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999; 44: 105-110.
Bunn PAJ. Incorporation of pemetrexed (ALIMTA) into the treatment of non-small cell lung cancer. Seminars in Oncology 2002; 29: 17-22.
Bunz F, Hwang PM, Torrace C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 194: 263-269.
Bustin SA e Dorudi S. Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Mol Med Today 1998; 4: 389-396.
Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology 2000; 25: 169-193.
Calabrese EJ. Biochemical individuality; the next generation. Reg Toxicol Pharmacol 1996; 24: 558-567.
Calabrese EJ. Biochemical individuality; the next generation. Reg Toxicol Pharmacol 1996; 24:558-567.
Calvert H e Walling JW. Clinical studies whit MTA. B J of Cancer 1998; 78: 35-40.
Calvert H e Walling JW. Folate status and the safety profile of antifolates. Semin Oncol 2002; 29: 3-7.
Campodonico F, Canepa G, Capponi G, et al. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Anticancer Res 2005; 25: 2381-4.
Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
Carreras CW e Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995; 64: 721-762.
Cartee L e Kucera GL. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 1998;
41: 403-412.
Chabot GG. Factors involved in clinical pharmacology variability in oncology.
Anticancer Res 1994; 14: 2269-2272.
Chen AY, Scruggs PB, Geng L, et al. p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells Ann N Y Acad Sci 2000; 922: 298-300.
Chen MJ, Shimada T, Moulton AD, The functional human dihydrofolate reductase gene. J Biol Chem 1984; 259: 3933-3943.
Chen VJ, Bewley JR, Andis SL,et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998; 78: 27-34.
Chen VJ, Bowley JR, Andis SL,et al. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM CELLS. Semin Oncol 1999; 26: 48-54.
Chester JD, Hall GD, Forster M, Protheroe AS.
Chong L e Tattersall MHN. 5,10-dideazatetrahydrofolic acid reduces toxicity and deoxyadenosina triphosphate pool expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase. Biochemical Pharmacol 1995; 49: 819-827.
Chottiner EG, Shewach DS, Datta N et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 1991; 88: 1531-1535.
Chou TC, Stepkowski S e Kahan BD. Computerized quantitation of immunosuppressive synergy for clinical protocol design. Transplant Proc 1994; 26: 3043- 3045.
Chow M e Rubin H. Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin. Proc Natl Acad Sci USA 1998; 95: 4550-4555.
Chu E e Allegra CJ. The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 1996; 36: 143-63.
Chu E, Copur SM, Ju J et al. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 1999; 19: 1582-1594.
Chu E, Drake JC, Koeller DM, et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39: 136-143.
Chu E, Takimoto CH, Voeller D, et al. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemestry 1993;
32: 4756-4760.
Ciardiello F e Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
Clark R, Ihde DC. Small-cell-lung-cancer: treatment progress and prospects.
Oncology 1998; 12: 647-658.
Climie S, Ruiz-Perez L, Gonzalez-Pacanowska D, Prapunwattana P, Cho SW, Stroud R e Santi DV. Saturation site-directed mutagenesis of thymidylate synthase. J Biol Chem 1990; 265: 18776-18779.
Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Clin Cancer Res 2004; 10: 6622-8.
Collins BJ, Deak M, Arthur JS, et al. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J 2003; 22: 4202-4211.
Compton MM. A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. Cancer Metastasis Rev 1992; 11: 105-119.
Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signalling in carcinoma cells. Oncogene 2002;
21: 4032-4041.
Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G.
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.
Clin Cancer Res. 1999 Sep;5(9):2629-37
Dancey J e Le Chevalier T. Non-small-cell-lung-cancer: an overwiev on current management. Eur J Cancer 1997; 33: 2-7.
Datta NS, Shewach DS, Hurley Mc, et al. Human T-lymphoblast deoxycytidine kinase: purification and properties. Biochemistry 1989; 28: 114-123.
Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
Daujat S, Neel H, Piette J. MDM2: life without p53. Trends Genet 2001; 17: 459-464.
De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93: 491-4.
Del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
Demontis S, Terao M, Brivio M, et al. Isolation and characterization of the gene coding for human cytidine deaminase. Biochim Biophys Acta 1998; 1443: 323-333.
Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41:23-26.
Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41:23-26.
Dive C e Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 1991; 64: 192-196
Dosaka-Akita H, Katabami M, Hommura H,et al. Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 1999; 56: 259-264.
Dumontet C, Bauchu EC, Fabianowska K, et al. Common resistance mechanism to nucleoside analogues in variants of the human erytroleukemic line K562. Adv Exp Med Biol 1999; 457: 571-577.
Eda H, Ura M, F-Ouchi K et al. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res 1998; 58: 1165-1169.
Edelman MJ, Quam H e Mullinis B. Iteractions of gemcitabine, carboplatin and pacitaxel in molecularly defined non-small cell lung cancer cell lines. Cancer Chemother Pharmacol 2001; 48: 141-144.
Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 1407-27.
Eliopoulus N, Cournoyer D e Momparler RL. Drugs resistance to 5-aza-2’- deoxicytidine arabinoside conferred by retroviral mediated transfer of human cytidine deanimase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42: 373-378.
Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med 2000; 93: 391-423; Roses AD.
Pharmacogenetics and the pratice of medicine. Nature 2000; 405: 857-65
Evans WE, Relling MV. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999; 289: 487-491.
Evans WE, Relling MV. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999; 289:487-491.
Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natrl Acad Sci USA 1998; 95: 13176-13181.
Ferre F. Quantitative or semi-quantitative PCR: reality versus myth. PCR Methods Appl 1992; 2: 1-9.
Ferreira CG, Span SW, Peters GJ,et al. Chemotherapy triggers apoptosis in a caspase- 8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000; 60: 7133-7141.
Ferreira CG, Tolis C, Span SW, et al. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000; 6:
203-212.
Ferreira R, Naguibneva I, Mathieu M, et al. Cell cycle-dependent recruitment of HDAC-1 correlates with deacetylation of histone H4 on an Rb-E2F target promoter. EMBO Rep 2001; 2: 794-799.
Flocke K e Mannherz HG. Isolation and characterization of 5'-nucleotidase of a human pancreatic tumor cell line. Biochim Biophys Acta 1991; 1076: 273-281.
Fogh J e Trempe G. Human Tumor Cells In Vitro. J Natl Cancer Inst 1997; 58: 209- 214.
Fossella F, Rigas JR e Belani CP. New options in the treatment of non-small-cell- lung-cancer. Anticancer Drugs 1999; 10: S25-S28.
Fossella FV e Gatzemeier U. Phase trials of pemetrexed. Semin Oncol 2002; 29: 8-16.
Fresno Vara JA, Casado E, de Castro J, el al. PI3K/Akt signalling pathway and cancer.
Cancer Treat Rev 2004; 30: 193-204.
Friess H, Lu Z, Graber HV, et al. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998; 43: 414-21.
Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507.
Fukuoka K, Adachi J, Nishio K, et al. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997; 88: 1009-1016.
Galmarini CM, Mackey JR e Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-890.
Gandara DR, Edelman MJ, et al. Current status and novel therapeutic approaches in advanced non-small-cell-lung-cancer. ASCO-Educational Book 1999: 362-369.
Gandhi V, Huang P e Xu YZ. Modulatory acticity of 2',2'-difluoro-deoxicytydine on the phosphorilation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3675- 3680.
Gandhi V, Mineishi S e Huang P. Cytotossicity, metabolism and mechanism of action of 2',2'-difluoro-deoxyguanosine in the chinese hamster ovary cells. Cancer Res 1995; 55:
1517-1524.
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008.
Gardmark T, Carringer M, Beckman E, Malmstrom PU; Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology. 2005 Sep;66(3):527-30
Geradts J, Fong KM, Zimmerman PV, et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999; 5: 791-800.
Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors:
establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;
51: 1417-1423.
Gibson UE, Heid CA e Williams PM. A novel method for real time quantitative RT- PCR. Genome Res 1996; 6: 995-1001.
Ginsberg RJ, Vokes EE e Raben A. Non small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and practice of oncology. 4th ed.
Philadelphia. Lippincott-Raven, 1997: 858-910.
Giovannetti E, Mey V, Danesi R, et al. Synergistic Cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancar cell lines. Clin Cancer Res 2004; 10: 2936-2943.
Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.
Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66: 3928-3935.
Goan YG, Zhou B, Hu E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycitidine in the human KB cancer cell line.
Cancer Res 1999; 59: 4204-4207.
Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004 Sep;46(3):339-43
Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041-1048.
Gourdeau H, Clarke ML, Ouellet F, et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001; 61: 7217-7224.
Gourney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 9: 2590-2611.
Gourney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 9:2590-2611.
Greene PJ, Maley F, Pedersen-Lane J e Santi DV. Catalytically active cross-species heterodimers of thymidylate synthase. Biochemistry 1993; 32: 10283-10288.
Griffith DA, Jarvis SM Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 29:153-181.
Grilli R, Oxman AD e Julian JA. Chemotherapy for advanced non-small-cell-lung- cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
Habeck LL, Leitner TA, Shackelford KA, et al. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res 1994; 54: 1021- 1026.
Habeck LL, Mendelsohn LG, Shih C,et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995; 48: 326-333.
Haldar S, Basu A e Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
Hanada M, Feng J, Hemmings BA.Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16
Hanauske AR, Chen V, Paoletti P e Cletniyikiza T. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist 2001; 6: 363-373.
Hapke DM, Stegmann AP e Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996; 56: 2343.
Heinemann V, Hertel LW, Grindey GB e Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D- arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-4031.
Heinemann V, Schultz L, Issels RD, et al. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995; 22: 11-18.
Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF- CEM cells by 2’,-2’difluorodeoxycytidine. Mol Pharmacology 1990: 38; 567-572.
Heinemann V, Xu YZ, Chubbs S, et al. Cellular elimination of 2',2'- difluorodeoxycytidine 5’- triphosphate: a mechanism of self-potentiation. Cancer Res 1992;
52: 533-539.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol.
2003 Dec 1;21(23):4342-9
Heldin C-H e Rönnstrand L. Growth factor receptors in cell tranaformation, In:
Oncogene and tumor suppressors 1997; pp 55-85, IRL Press, Oxford.
Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 1990; 50: 4417-4422.
Hickman JA, Beere HM, Wood AC, et al. Mechanisms of cytotoxicity caused by antitumour drugs. Toxicol Lett 1992; 64-65: 553-561.
Hicks-Berger CA, Yang F, Smith TM, et al. The importance of histidine residues in human ecto-nucleoside triphosphate diphosphohydrolase-3 as determined by site-directed mutagenesis Biochim Biophys Acta 2001; 1547: 72-81.
Higushi R, Fockler C, Dollinger G, et al. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology 1993; 11: 1026-1030.
Holden JA. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. Ann Clin Lab Sci 1997; 27: 402-412.
Hsueh CT, Chiu CF, Kelsen DP e Schwartz GK. Selective inhibition of cyclooxygenase- 2 enhances mitomycin-C-induced apoptosis Cancer Chemother Pharmacol 2000; 45: 389- 396.
Huang P e Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995; 22:
19-25.
Huang P, Chubb S, Hertel LW, et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991 15; 51: 6110-6117.
Huang Y, Ray S, Reed JC, et al. Estrogen increases intracellular Bcl-2 to Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997; 42:73-81.
Hui YF e Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997; 54: 162-170.
Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high dose and standard dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-9
Itoh R, Echizen H, Higuchi M, et al. A comparative study on tissue distribution and metabolic adaptation of IMP-GMP 5'-nucleotidase. Comp Biochem Physiol B 1992; 103:
153-159.
Iwasaki H, Huang P, Keating MJ, et al. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270-278.
Iyer L, Ratain MJ. Clinical Oncology Update Pharmacogenetics and Cancer Chemotherapy. Eur J Cancer 1998; 34:1493-1499.
Jacobs AD. Gemcitabine-Based Therapy in Pancreas Cancer. Cancer Supplement 2002; 95: 923-940.
Jahns-Streubel G, Reuter C, Auf der Landwehr U, et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD- 9 induction therapy in acute myeloid leukemia. Blood 1997; 90: 1968-1976.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ.
Johnson DH. Evolution of cisplatin-based chemotherapy in non small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience.
Chest 2000; 117: 133S-137S.
Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89: 308-213.
Johnstone RW, Ruefli AA e Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
Jolivet J, Jansen G, Peters GJ et al. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate Biochem Pharmacol 1994; 47: 659-665.
Kan JL e Moran RG. Intronic polyadenylation in the human glycinamide ribonucleotide formyltransferase gene. Nucleic Acids Res 1997; 25: 3118-3123.
Kaneda S, Nalbantoglu J, Takeishi K, et al. Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 1990; 265: 20277-20284.
Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997; 24: 8-16.
Kaufmann SH. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 1996; 2: 298-303.
Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J of Cancer 1998; 78: 1-7.
Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901.
Kindler H, Strickland D, Dugan W, et al. Phase II trial of Alimta plus Gemzar administered every 21 days in patients with advanced cancer. Eur J Cancer 2001; 37: 1152- 1158
Kitchens ME, Forsthoefel AM, Barbour Kw, et al. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. Mol Pharmacol 1999; 56:
1063-1070.
Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;
45: 1437-1443.
Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000; 83: 1069-1070.
Kroep JR, van Moorsel CJ, Veerman G, et al. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). Adv Exp Med Biol 1998; 431: 657-660.
Kuhn K, Bertling WM e Emmrich F. Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation.
Biochem Biophys Res Commun 1993; 190: 1-7.
Kumar P, Kisliuk RL, Gaumont Y, et al. Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells. Biochem Pharmacol 1990;
40: 2651-2660.
Kwok JBJ e Tattersal MHN. DNA fragmentation, L1210 cells. Br J of Cancer 1992; 65:
503-550.
La Thangue NB. The retinoblastoma gene product and its relatives, In: Oncogene and tumor suppressors 1997; pp 233-259, IRL Press, Oxford.
Lalibertè J e Momparler RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA Cancer Res 1994; 54: 5401-5407.
Lalibertè J, Marquez VE e Momparler RL. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 1992; 30: 7-11.
Lawrence TS, Chang EY, Hahn TM, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Cancer Res 1997; 3: 777-782.
Lawrence TS, Eisbruch A e Shewach DS. Gemcitabine-mediated radiosensitization.
Semin Oncol 1997; 24: 24-27.
Le Chavalier T. Gemcitabine and pemetrexed (ALIMTA) in thoracic cancer: present and future perspectives. Introduction and current controversies. Semin Oncology 2002;
29: 43-46.
Li WW, Lin JT, Schweitzer BI, et al. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res 1992; 52: 3908-3913.
Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay.
Genetic Anal 1999; 14: 143-149.
Longley DB, Bover J, Allen WL, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
Cancer Res 2002; 62: 2644-2649
Loni L, Del Tacca M e Danesi R. Pharmacogenetics of anticancer drugs in non- Hodgkin lymphomas. Br J Cancer 2001 16; 85: 1425-1431
Loprevite M, Favoni RE, de Cupis A, et al. A Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int J Oncol 1999; 15: 787-792.
Lu X, Errington J, Chen VJ, et al. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 2000; 6: 271-277.
MacDonald SG e McCormick F. RAS/RAF/ERK signal transduction pathway, In:
Oncogene and tumor suppressors 1997; pp 121-153, IRL Press, Oxford.
Mackey JR, Mani RS, Selner M, el al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;
58: 4349-4357.
Manegold C, Drings P, von Pawel J, et al. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Semin Oncol 1997; 13-17.
Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 2000; 18: 29-42.
Manegold C. Chemotherapy for advanced non-small-cell-lung-cancer. Semin Oncol 2001; 28: 1-6.
Mansson E, Spasokoukotskaja T, Sallstrom J, et al. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Cancer Res 1999; 59: 5956-5963.
Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell-lung-cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999; 44: 1125-1135.
Matera M, Costantino G, Clementi G, Lempereur L, Vasta D, Vasquez E.
Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder. Oncol Rep. 2004 Jun;11(6):1145-51
Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 2005; 25: 2493-2496.
Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolate in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002; 63: 105-115.
Mc Donald AC, Vasey PA, Adams L, et al. A phase I study of LY231514 the multitargeted antifolate. Clin Cancer Res 1998; 4: 605-610.
McCarthy JJ, Hilfiker R. The use of single nucleotide polymorphism maps in pharmacogenetics. Nature Biotechnol 2002; 18: 505-8
McLeod HL, Cassidy J, Powrie RH, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 2000; 6: 2677-2684.
Mendelshon LG, Soose DJ, Patel VF, et al. LY231514, a pirrolo ( 2,3-d) pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116- 1123.
Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26: 42-47.
Mendelsohn LG, Shih C, Schultz RM, et al. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs 1996; 14: 287-294.
Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59: 107-114.
Minamiya Y, Matsuzaki I, Sageshima M, et al. Expression of tissue factor mRNA and invasion of blood vessels by tumor cells in non-small cell lung cancer. Surg Today 2004;
34: 1-5.
Miwa M, Eda H, Ura M, et al. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'- methylidenecytidine. Clin Cancer Res 1998; 4: 493-497.
Momparler RL, Eliopoulos N, Bonenzi V, et al. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther 1996; 3: 331-338.
Momparler RL, Laliberte J, Eliopoulos N, et al. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside.
Anticancer Drugs 1996; 7: 266-274.
Monod J. Il caso e la necessità 1974.
Motulsky AG. Drug reactions, enzymes, and biochemical genetics. JAMA 1957; 165:
835-836.
Mullis KB e Faloona FA. Specific Synthesis of DNA in vitro via a polymerase- catalyzed chain reaction. Methods Enzymol 1986; 155: 335-350.
Nabholtz JM e Riva A. The choice of adjuvant combination therapies with taxanes:
rationale and issues addressed in ongoing studies. Clin Breast Cancer 2001; 2: 7-14.
Nakashio A, Fujita N, Rokudai S, et al. Prevention of phosphatidylinositol 3'-kinase- Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 2000; 60:
5303-5309.
Neff T e Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-1346.
Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
Ng SSW, Tsao MS, Chow S e Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
Noble S e Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997; 54: 447-472.
Noda N, Matsuzoe D, Konno T, et al. K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep 2001; 8: 889-892.
Novello S e Le Chevalier T. ALIMTA (pemetrexed disodium, LY231514): clinical experience in non-small cell lung cancer. Lung Cancer 2001; 34: 107-109.
NSCLC Collaborative Group. Chemotherapy in non-small-cell-lung-cancer: a meta- analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
Numico G, Russi E e Merlano M. Best supportive care in non-small-cell-lung-cancer:
is there a role for radiotherapy or chemotherapy? Lung Cancer 2001; 32: 213-226.
Oka J, Matsumoto A, Hosokawa Y e Inoue S. Molecular cloning of human cytosolic purine 5'-nucleotidase. Biochem Biophys Res Commun 1994; 205: 917-922.
Oldach D. “Real Time” Polimerase chain reaction. Gastroenterology 1999; 205: 917- 922.
Orlando C, Pizzani P e Pazzagli M. Developments in quantitative PCR. Clin Chem Lab Med 1998; 36: 255-269.
Ostruszka LJ e Shewach DS. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer Res 2000; 60: 6080-6088.
Pace E, Melis M, Siena L, et al. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 2000; 46: 467-476.
Palou J, Carcas A, Segarra J, et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 2004; 172: 485-488.
Pao W, Miller VA, Venkatraman EV, Kris MG. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for Pakt? J Nat Cancer Inst 2004; 96 (15): 1117-9
Park HS, Kim MS, Huh SH, Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 2002; 277: 2573-2578.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan- Feb;49(1):33-64, 1.
Pauletti G, Lai E e Attardi G. Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines Proc Natl Acad Sci USA 1990; 87: 2955-2959.
Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev 2000; 14: 1027-1047.
Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
Pesi R, Turriani M, Allegrini S, et al. The bifunctional cytosolic 5'-nucleotidase:
regulation of the phosphotransferase and nucleotidase activities. Arch Biochem Biophys 1994; 312: 75-80.
Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22: 72-79.
Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253.
Pievani T. Introduzione alla filosofia della biologia 2005.
Pillai R. Oncogenes and oncoproteins as tumor markers. Eur J Surg Oncol 1992; 18:
417-424.
Pines J. Mammalian cell cycle control, In: Oncogene and tumor suppressors 1997; pp 189-232, IRL Press, Oxford.
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R e Gandhi V. Gemcitabine metabolism, mechanism of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
Plunkett W. Gemcitabine: preclinical pharmacology and mechanisms of action.
Semin Oncol 1996; 23: 3-15.
Poplin E, Roberts J, Tombs M, et al. Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs 1999; 17: 57-62.
Poruchynsky MS, Wang EE, Rudin CM, et al. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 1998; 58: 3331-3338.
Postmus PE e Bunn PA. Pemetrexed as a single agent in the terapy of avanced lung cancer. Semin Oncol 2002; 29: 17-22.
Postmus PE, Schramel FM e Smit EF. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. Semin Oncol 1998; 25: 79-82.
Pressacco J, Wiley JS, Jamieson GP, et al. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 1995; 72: 939-42.
Qiu J. Unfinished symphony. Nature 2006; 441: 143-145
Rajkumar SV e Adjei AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treatment Reviews 1998, 24: 35-53.
Rajkumar SV e Adjei AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treatment Reviews 1998, 24: 35-53.
Ramachandran C e Melnick SJ. Multidrug resistence in human tumors – molecular diagnosis and clinical significance. Molecular Diagnosis 1999; 4: 35-53.
Rauchwerger DR, Firby PS, Hedley DW e Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60: 6075- 6079.
Ren Q, Kao V e Grem JL Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818.
Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13: 2842-2850.
Rom WN, Hay JG, Lee TC, et al. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 2000; 161: 1355-1367.
Rosell R e Crinò L. Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncology 2002; 29: 23-29.
Rosell R, Monzo M, Pifarre A, et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 1996; 2: 1083-1086.
Ross DD e Cuddy DP. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 1994; 48: 1619-1630.
Ruiz van Haperen VW e Peters EGJ. New targets for pyrimidine antimetabolites for the treatment of solid tumors. Deoxictidine kinase. Pharm World SCI 1994; 16: 104-112.
Ruiz van Haperen VW, Bergman AM, Veerman G, et al. Preclinical combination therapy with gemcitabine and mechanism of resistance. Semin Oncol 1996; 23: 16-24.
Ruiz van Haperen VW, Veerman G, Boven E, et al. Schedule-dependence of sensitivity to 2’,2’-difluorodeoxycitidine (gemcitabine) in relation. Biochem Pharmacol 1994; 48: 1327-1339.
Ruiz van Haperen VW, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2',2'-difluorodeoxycyctidine-resistant variant of the human ovarian carcinoma call line A2780. Cancer Res 1994; 54: 4138-4143.
Ruiz van Haperen VW, Veerman G, van Morseel CJ, et al. Induction of in vivo resistance against gemcitabine. Adv Exp Med Biol 1998; 431: 637-640.
Ruiz van Haperen VW, Veerman G, Vermorken, et al. 2',2'-difluoro-deoxicytidine (gemcitabine) incorporation into RNA and DNA from tumor cell lines. Biochem Pharmacol 1993; 46: 762-766.
Saccone S, Besati C, Andreozzi L, et al. Assignment of the human cytidine deaminase (CDA) gene to chromosome 1 band p35-p36.2. Genomics 1994; 22: 661-662.
Sakorafas GH, Lazaris A, Tsiotou AG, et al. Oncogenes in cancer of the pancreas. Eur J Surg Oncol 1995; 21: 251-253.
Sakorafas GH, Tsiotou AG e Tsiotos GG. Molecular biology of pancreatic cancer;
oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treatment Reviews 2000; 26: 29-52
Salgia R e Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16:
1207-1217.
Sanchez-Cespedes M, Reed AL, Buta M, et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999; 18:
5843-5849.
Sandler A e Ettinger DS. Gemcitabine: single agent and combination therapy in non small cell lung cancer. The Oncologist 1999; 4: 241-251.
Scheffer GL, Schroeijers AB e Izquierdo MA. Lung resistance-related protein/majior valut protein and valuts in multidrug-resistant cancer. Curr Opin Oncol 2000; 12: 550-556.
Schultz RM, Chen VJ, Beweley JR, et al. Biological activity of the multitarget antifolate, MTA (LY231514) in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999; 26: 68-73.
Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19: 437- 443.
Schulz L, Schalhorn A, Wilmanns W, et al. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol 1998; 17: 965-971
Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005;
65: 65-69.
Sgroi DC, Tng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999; 59: 124-129.
Shackney SE e Shankey TV. Common patterns of genetic evolution in human solid tumors. Cytometry 1997; 29: 1-27.
Shah MA e Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7: 2168-2181.
Shah SA, Potter MW, Callery MP. Ubiquitin proteasome pathway: implication and advances in cancer therapy. Surg Oncol 2001; 10: 43-52.
Sherbet GW e Lakshmi MS. The genetics of cancer. Accademic press, San Diego.
Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994; 54: 3218- 3223.
Shewach DS, Reynolds KK e Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol pharmacology 1992; 42: 518-524.
Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123.
Shultz RM e Dempsey JA. Sequence dependence of ALIMTA (LY231514, MTA) with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res 2001; 21: 3209- 3214.
Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66: 431-438.
Sirotnak FM, Danenberg KD, Chen J et al. Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms. Biochem Biophys Res Commun 2000;
269: 21-24.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
Smid K, Van Moorsel CJ, Noordhuis P, et al. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int J Oncol 2001; 19: 157-162.
Smith GK, Duch DS, Dev IK, et al. Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase. Cancer Res 1992; 52: 4895-4903.
Smith PG, Marshman E, Calvert AH, et al. Prevention of thymidine and hypoxantine rescue from MTA (LY231514) growth inhibition by dypiridamole in human lung cancer cell lines. Semin Oncol 1999; 26: 63-67.
Smith PG, Marshman E, Newell DR, et al. Dipyridamole potentiates the in vitro actyvity of MTA (LY231514) by inhibition of thymidine transport. Br J of Cancer 2000; 82:
924-930.
Smith SG, Lehman NL e Moran RG. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 1993; 53:
5697-5706.
Song JJ, Walker S, Chen E, et al. Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc Natl Acad Sci 1993; 90: 431-434.
Souaze F, Ntodou-Thome A, Tran CY, et al. Quantitative RT-PCR: limits and accuracy. Biotechniques 1996; 21: 280-285.
Srimatkandada S, Schweitzer BI, Moroson BA, et al. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem 1989; 264: 3524-3528.
Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
Steward WP. Combination studies with gemcitabine in the treatment of non-small- cell lung cancer. Br J of Cancer 1998; 78: 15-19
Stone SR, Montgomery JA e Morrison JF. Inhibition of dihydrofolate reductase from bacterial and vertebrate sources by folate, aminopterin, methotrexate and their 5-deaza analogues. Biochem Pharmacol 1984; 33: 175-179.
Strauss GM, Langer MP, Elias AD, et al. Multimodality treatment of stage IIIA non small cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol 1992; 10: 829-838.
Strobel T, Kraeft SK, Chen LB, et al. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemiotherapy- induced cell death. Cancer Res 1998; 58: 4776-4781.
Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. Cancer Treat Rev. 2004 Jun;30(4):343-58.
Szabo D, Keyzer H, Kaiser HE, et al. Reversal of multidrug resistance of tumor cells Anticancer Res 2000; 20: 4261-4274.
Szende B, Zalatnai A e Schally AV. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci 1989; 86: 1643-1647.
Tan B, Piwnica-Worms D e Ratner L. Multidrug resistance transporters and madulation. Curr Opin Oncol 2000; 12: 450-458.
Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992; 35: 4450-4454.
Taylor WR e Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;
20: 1803-1815.
Teicher BA, Chen V, Chuan S, et al. Treatment regimes including the multitarget LY231514 in human tumors xenografts. Clin Cancer Res 2000; 6: 1016-1023.
Tesei A, Ricotti L, De Paola F, et al. In vitro schedule-dependent interactions between the multitarget antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002; 8: 233-239.
The Genome International Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860.
Theodossiou C, Cook JA, Fisher J, et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825-832.
Toffoli G, Veronesi A, Boiocchi M, et al. MTHFR gene polymorphism and severe toxicity during adjuvant trarment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000; 11: 373-374.
Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531.
Tonkinson JL, Worzalla JF, Teng C, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-3676.
Tritton TR. Cell surface actions of adriamycin. Pharmacol Ther 1991; 49: 293-309.
Tsai CM, Chang KT, Li L, et al. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000; 91: 213- 222.
Tseng JE, Kemp BL, Khuri FR, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59: 4798-4803.
Tsurusawa M, Niwa M, Katano, et al. Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells. Cancer Res 1988; 48: 4288-4293.
van der Kolk DM, de Vries EG, van Putten WJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
Clin Cancer Res 2000; 6: 3205-3214.
van Kuilemburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluoruracil- associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712.
van Moorsel CJ, Bergman AM, Veerman G, et al. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta 2000; 1474: 5-12.
van Moorsel CJ, Pinedo HM, Smid K, et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420-2429.
van Moorsel CJ, Veerman G, Ruiz van Haperen VW, et al. Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines. Adv Exp Med Biol 1998; 431:
661-665.
van Triest B, Pinedo HM, van Hensberger Y, et al. Thymidylatesynthase level as the main predictive parameter for sensitivity to 5-fluoruracil, but not for folate based thymidylate synthase inhibitors, in 13 non selectted colon cancer cell lines. Clin Cancer Res 1999; 5: 643-654.
Venter JC. The sequence of the human genome. Nature 2001; 291: 1304.
Vessel E. Advances in Pharmacogenetics and Pharmacogenoomics. J Clin Pharmacol 2000; 40: 930-938.
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol 2000;18 : 3068-3077.
von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602- 4608.
Wang J, Liu X e Jiang W. Expression of LRP, MRP and MDR1 in non-small cell lung cancer and its clinical significance. Zhonghua Zhong Liu Za Zhi. 2000; 22: 304-307.
Wang T e Brown MJ. mRNA quantification by real-time TaqMan polymerase chain reaction: validation and comparison with Rnase protection. Anal Biochem 1999; 269: 198- 201.
Wang Y, Zhaor R, Goldmann ID, et al. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the
pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003; 65: 1163-1170.
Webley SD, Welsh SJ, Jackman A, et al. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J of Cancer 2001; 85: 446-452.
Welsh SJ, Titley J, Brunton L, et al Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Clin Cancer Res 2000; 6: 2538-2544.
White EL, Shaddix SC, Brockman RW, et al. Comparison of the actions of 9-beta-D- arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 1982; 42: 2260-2264.
Wistuba II, Gazdar AF e Minna JD. Molecular genetics of small cell lung carcinoma.
Semin Oncol 2001; 28: 3-13.
Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA.
Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol. 2004 Feb;45(2):182-6;
Witjes JA, Vriesema JL, van der Heijden AG, Peters GJ, Schalken JA.
Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol 2003;
44: 615-619.
Wolf P, Hu YC, Doffek K, et al. O6-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 2001; 61: 8113-8117.
Wong SJ, Myette MS, Wereley JP e Chitambar CR. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin Cancer Res 1999; 5: 439-443.
Worden FP e Kalemkerian GP. Therapeutic advances in small cell lung cancer. Invest Drugs 2000; 9: 565-579.
Worku Y, Luzio JP e Newby AC. Identification of histidyl and cysteinyl residues essential for catalysis by 5'-nucleotidase FEBS Lett 1984; 167: 235-240.
Wright JA, Chan AK, Choy BK, et al. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol 1990; 68: 1364-1371.
Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 1992; 11: 95-103.
Xiaohong L, Errington J, ChenVJ, et al. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 2000; 5: 271- 277.
Xu YZ e Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol 1992; 44: 1819- 1827.
Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti- inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298: 976-985.
Yusa K, Oh-hara T, Tsukahara S, et al. Human immunodeficiency virus type 1 induces 1-beta-D-arabinofuranosylcytosine resistance in human H9 cell line. J Biol Chem 1992;
267: 16848-16850.
Zamorano PL, Mahesh VB e Brann DW. Quantitative RT-PCR for neuroendocrine studies. A minireview. Neuroendocrinology 1996; 63: 397-407.
Zhang J e Byrne CD. Differential priming of RNA template during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative reverse-transcriptase PCR. Biochemical Journal 1999; 337: 231-241.
Zhao R, Gao F, Wang Y, et al. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2001;
276: 1114-1118.
Zimmermann H. 5'-Nucleotidase: molecular structure and functional aspects. J Biochem 1992; 285: 345-365.
Zoli W, Ricotti L, Dal Susino M, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 1999; 81: 609-615.
